India's drug pricing authority to be probed

2 October 2000

The Indian government is aware of complaints against the drugprice-fixing methods adopted by the National Pharmaceutical Pricing Authority, according to the Minister for Chemicals and Fertilizers, Suresh Prabhu.

He is quoted by the Financial Express as saying that the Ministry has directed the Comptroller and Auditor General of India to conduct an in-depth audit on the NPPA. "Our idea is to bring total transparency into the working of the organization," said Mr Prabhu, adding: "the new price control mechanism will make use of modern tools for monitoring prices."

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight